Name in SEC filings: BriaCell Therapeutics Corp.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| BriaCell public offering 2026-01-15 | Other | Stage not stated | January 15, 2026 | 8-K · |
| BriaPro sCD80 license transaction | Other | Stage not stated | by the end of March 2026 | 10-Q · |
| BriaCell public offering 2026-06-02 | Other | Stage not stated | June 2, 2026 | 8-K · |
| BriaPro TILsRx | Other | Stage not stated | 2028 | 8-K · |
Source: ORION, orionbiotechai.com/company/BCTX, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/BCTX
BriaPro TILsRx · Other · 2028
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
OtherJanuary 15, 2026
Stage: Not stated
Public float: $94,477,705 · as of · SEC filing
The offering is expected to close on January 15, 2026, subject to satisfaction of customary closing conditions.
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-01)
Otherby the end of March 2026
Stage: Not stated
Public float: $94,477,705 · as of · SEC filing
The Transaction is expected to close by the end of March 2026, subject to certain conditions including (i) approval of the disinterested shareholders of BriaPro, and (ii) receipt of a third-party valuation confirming that the Transaction is occurring at fair market value.
SEC timing context:
On February 18, 2026, the Company and BriaPro, announced that they have entered into a definitive purchase agreement (the “Purchase Agreement”) pursuant to which BriaPro has agreed to purchase BriaCell’s exclusive license to develop and commercialize Soluble CD80 (“sCD80”) as a biologic agent for the treatment of cancer and other associated assets (the “Transaction”). Under the terms of the Purchase Agreement, BriaPro gains the worldwide rights to develop and commercialize sCD80 as a therapeutic agent for the treatment of cancer, while UMBC holds all rights, title and interest in the inventions and the patent, except for certain rights retained by the United States Government. BriaPro will pay 2% royalties to UMBC upon the commercialization of the product plus other development costs. As part of the Transaction, BriaCell will make available to BriaPro up to $3 million to fund research and development efforts (the “Credit Facility”). Each drawdown under the Credit Facility will be subject to BriaCell’s approval regarding the use of funds. As consideration for the transfer of the exclusive license and the Credit Facility, BriaPro will issue to BriaCell 23,972,589 Common Shares at an aggregate value of approximately C$1.18M, increasing BriaCell’s interest in BriaPro to approximately 78% post-transaction.
10-Q · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-03)
OtherJune 2, 2026
Stage: Not stated
Public float: $94,477,705 · as of · SEC filing
The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions.
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-06)
Other2028
Stage: Not stated
Public float: $94,477,705 · as of · SEC filing
Human clinical studies are expected to be initiated in 2028, pending funding.
SEC timing context:
BriaPro also expects to select at least one TILsRx candidate to advance into IND enabling studies.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2028-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| BriaPro TILsRxOther | 2028“Human clinical studies are expected to be initiated in 2028, pending funding.” Filed · EX-99.2 | Period not started The stated period has not started yet, so there is nothing to compare. |
| BriaCell public offering 2026-06-02Other | June 2, 2026“The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions.” Filed · EX-99.1 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| BriaPro TILsRxOther | first half of 2027“Human clinical studies are expected to be initiated in the first half of 2027, pending funding.” Filed · EX-99.2 | Period not started The stated period has not started yet, so there is nothing to compare. |
| BriaPro sCD80 license transactionOther | by the end of March 2026“The Transaction is expected to close by the end of March 2026, subject to certain conditions including (i) approval of the disinterested shareholders of BriaPro, and (ii) receipt of a third-party valuation confirming that the Transaction is occurring at fair market value.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| BriaPro sCD80 license transactionOther | on or around March 12, 2026“The Transaction is expected to close on or around March 12, 2026, subject to certain conditions including (i) approval of the disinterested shareholders of BriaPro, and (ii) receipt of a third-party valuation confirming that the Transaction is occurring at fair market value.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| BriaCell public offering 2026-01-15Other | January 15, 2026“The offering is expected to close on January 15, 2026, subject to satisfaction of customary closing conditions.” Filed · EX-99.1 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| BriaPro TILsRxOther | first half of 2027“Human clinical studies are expected to be initiated in the first half of 2027, pending funding.” Filed · EX-99.2 | Period not started The stated period has not started yet, so there is nothing to compare. |
| BriaPro TILsRxOther | first half of 2027“Human clinical studies are expected to be initiated in the first half of 2027, pending funding.” Filed · EX-99.2 | Period not started The stated period has not started yet, so there is nothing to compare. |
| BriaPro TILsRxOther | first half of 2025“Human clinical studies are expected to be initiated in the first half of 2025.” Filed · 10-K | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| BriaPro TILsRxOther | first half of 2025“Human clinical studies are expected to be initiated in the first half of 2025.” Filed · EX-99.2 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| BriaPro TILsRxOther | first half of 2025“Human clinical studies are expected to be initiated in the first half of 2025.” Filed · EX-99.2 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| BriaPro TILsRxOther | first half of 2025“Human clinical studies are expected to be initiated in the first half of 2025.” Filed · EX-99.2 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| BriaPro TILsRxOther | first half of 2025“Human clinical studies are expected to be initiated in the first half of 2025.” Filed · EX-99.2 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| BriaPro TILsRxOther | first half of 2025“Human clinical studies are expected to be initiated in the first half of 2025.” Filed · 10-K | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for BCTX. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.